Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BETHANECHOL CHLORIDE

All products: general benefit

Other products in the same Health Canada class (N07A) — coverage varies; not interchangeable

  • Pyridostigmine (Mestinon): general benefit
  • Pilocarpine (Salagen): not a benefit

Duvoid · DIN 01947923 · 50mg · tablet

General benefitDormant since 2025-12-04 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Duvoid · DIN 01947923 Manufacturer: Knight Therapeutics Inc.; listing date 1996-10-01 Health Canada: Dormant since 2025-12-04 · brand DUVOID · ATC N07AB02 BETHANECHOL · form Tablet · route Oral · ingredients BETHANECHOL CHLORIDE 50 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Duvoid: Formulary list price $0.9921/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9921 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12887 · Verify on the e-Formulary ↗ (DIN 01947923)

Source record
DIN 01947923: Duvoid Raw flags: sec3=Y Item: 120400015; group id 190; item number 0350; lccId None; manufacturer id KNT Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.9921; ministry $0.9921 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01947923 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12887
Shortage status: active shortage (reported 2023-12-11, last updated 2024-01-24) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947923
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-12-04 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

DONEPEZIL HCL

· 48 products · Off-Formulary Interchangeable, not an ODB benefit (6), Limited Use, codes 347, 348 (42) · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE The treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. https://pdf.hres.ca/dpd_pm/00082692.PDF PM date: not printed or not captured Source product: DUVOID; DIN 01947931; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Duvoid · DIN 01947923 Shortage status: active shortage (reported 2023-12-11, last updated 2024-01-24) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947923

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)